Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.
Alkor Bio has developed a rapid and accurate microarray-based diagnostic assay for cystic fibrosis using Tecan’s HS 400™ Pro Hybridization Station and PowerScanner™, allowing one technician to screen 10 patients for 25 cystic fibrosis mutations in under seven hours.
A suite of Tecan’s microarray products is ensuring that researchers at the Biodesign Institute in Arizona, USA, forge ahead with a range of functional proteomics projects looking at early biomarkers for several diseases.
Scientists at the German Cancer Research Center are using an HS 4800™ Pro microarray hybridization station and a PowerScanner™ to investigate pancreatic cancers. By combining these automated solutions with in-house developed antibody microarrays, the Center is able to study pancreatic cancer at a protein level, helping to better understand the basic biology of the disease and develop new screening strategies for early detection.
Researchers at JPT Peptide Technologies are using Tecan's HS 4800™ hybridization station to improve throughput and give a high level of reproducibility for patient sera screening with the Company's own PepStar™ peptide microarray technology.
Novartis is using an HS 4800™ Pro hybridization station to help profile and select antibodies for development into new biopharmaceuticals, relying on the system's throughput and reproducibility to efficiently prepare Protagen UNIchip® microarrays for analysis.
Scientists at the National Institute of Molecular Genetics in Italy rely on the Freedom EVO® platform for automated diagnostic screening of sera from patients suffering from autoimmune diseases.
Scientists at the Biodesign Institute Center for Innovations in Medicine have increased their sample throughput and improved inter-assay variation using Tecan's HS 4800™ Pro microarray hybridization station.
In the last Tecan Journal we announced that Dr Francisco Quintana from the Harvard Medical School had become the first ever winner of the Tecan Detection Award. Dr Quintana’s laboratory is using a range of Tecan instruments – including a HS 4800™ Pro hybridization station, a PowerScanner™ and an Infinite® F200 microplate reader – as part of a systems biology approach to studying the role of the immune response in multiple sclerosis.
Researchers at McMaster University, Ontario, Canada, are developing protein microarrays for serum-based diagnostic testing. These microarrays, developed using a Tecan laser scanner, are able to combine autoimmunity, bacterial and viral antigens on a single array, and are helping researchers to investigate the link between infection and autoimmune disease.
HS 800™ Pro Hybridization Station. Exiqon is a Danish biotechnology company that provides products and services for the life sciences, research and drug discovery industries all over the world.
About one in 200 babies worldwide is born with a chromosomal abnormality and many of these children have mental retardation and learning disabilities. Chromosomal imbalances, such as deletions, microdeletions, translocations or inversions, underlie some of these disorders and the genetic diagnosis of these patients has conventionally relied on cytogenetic chromosomal analysis techniques, such as karyotyping, fluorescence in situ hybridization (FISH) or conventional comparative genomic hybridization (CGH).